stockstotrade.comSEP 42 min read$RARE

Ultragenyx Stock Crashes As GTX-102 Failure Erases Optimism

Ultragenyx Pharmaceutical (RARE) stock rose 3.37% before dropping 44.6% intraday after GTX-102 trial failure. The company reported $673M revenue, 87.8% gross margin, but -79% EBIT margin. Analysts see $15 as pivotal support, with targets reset to mid-20s to low-30s. The stock is now trading near $15.36.

Original reporting

stockstotrade.com

Published Sep 4, 2026, 8:18 PM UTC

Analysis

AlphAI AI DeskAI-generated

Added to AlphAI Sep 5, 2026, 12:51 PM UTC. Informational, not investment advice.

How this was made

AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About AlphAI AI Desk Scoring methodology Report an issue

Ultragenyx Stock Crashes As GTX-102 Failure Erases Optimism — source image — Source · stockstotrade.com

Decision brief

The 30-second read

$RAREBearishMed

Why it matters

The trial failure eliminates a key growth driver, resetting price targets lower and increasing short‑term volatility.

Market read

The news drives a sharp price decline and short‑term trading opportunities in the biotech sector.

What to watch

Potential for upcoming data on other programs and the impact of recent FDA approval of Genglycos.

Relevance 8/10Novelty 8/10Timing: today

Background

Ultragenyx (RARE) is a rare‑disease platform with strong revenue growth but high cash burn. Recent FDA approval of Genglycos contrasts with the GTX‑102 failure.

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$RAREBearishHigh confidence

Context

GTX-102 Phase 3 trial failure caused a 44.6% intraday drop, pushing the stock into the mid‑teens.

Expected impact

Further short‑term weakness toward $13 support; potential rebound only if new data emerges.

Evidence & confidence

Trial failure is a material, fresh event for a high‑risk biotech; the stock already fell 44% intraday, indicating strong sell pressure.

Market effects

Sector

Biotech sector may see broader risk aversion as trial failures raise concerns about pipeline reliability.

Regional

US biotech stocks could face short‑term pressure.

Global

Limited to biotech investors; no broad market effect.

Counterpoint

What could challenge this read

If the company has sufficient cash runway, a deep discount may present a long‑term buying opportunity.

Key entities

company
Ultragenyx Pharmaceutical Inc.
US‑listed biotech (NASDAQ: RARE) reporting GTX‑102 Phase 3 failure.

Read at source ← All news

SEP 17

$RAREHighAI 9/10

RARE Looks 68.1% Undervalued on GF Value™ After FDA Approval Boo

Ultragenyx (RARE) received FDA approval for its gene therapy Fayuvi, the first treatment for Type A Sanfilippo syndrome. The company's P/S ratio is 2.09, below its historical median of 16.1x. GuruFocus estimates RARE is 68.1% undervalued at $14.50 per share, but notes risks due to ongoing losses and cash burn. Insiders have sold $4.0M in shares in the past year.

gurufocus.com3 min

SEP 17

$RAREHighAI 9/10

Ultragenyx Pharmaceutical Inc. (RARE): Other Events

Ultragenyx Pharmaceutical Inc. (RARE) filed an SEC Form 8-K — Other Events. Item 8.01 Other Events. On September 17, 2026, Ultragenyx Pharmaceutical Inc. (“Ultragenyx” or the “Company”) announced that the U.S. Food and Drug Administration (the “FDA”) granted standard full approval of FAYUVI™ (rebisufligene etisparvovec-hopf), also known as UX111, for the

SEC EDGAR 8-K1 min

SEP 17

$RAREMedAI 9/10

A fatal childhood disease gets its first FDA-approved treatment

Ultragenyx (RARE) received FDA approval for FAYUVI, the first treatment for Sanfilippo syndrome Type A. The gene therapy showed a 23.5-point improvement in cognitive scores. Commercial availability is expected in 30–60 days, with risks including liver enzyme elevations and potential malignancy. The stock rose 2.05% post-announcement.

stocktitan.net2 min

SEP 17

$RAREHighAI 9/10

Ultragenyx stock surges 10% on FDA approval for gene therapy

Ultragenyx Pharmaceutical (RARE) shares rose 10% after the FDA approved Fayuvi, a gene therapy for mucopolysaccharidosis type IIIA. This is the first FDA-authorized treatment for this rare pediatric disease. The therapy showed improved cognitive function in clinical trials but carries risks like liver enzyme increases and potential long-term tumor development.

investing.com2 min

SEP 17

$RAREHighAI 9/10

Ultragenyx gets FDA approval for rare disease gene therapy

Ultragenyx Pharmaceutical received FDA approval for Fayuvi, a gene therapy for Sanfilippo syndrome Type A. The treatment targets the enzyme deficiency causing the disease. Ultragenyx shares rose 6% on the news.

investing.com1 min

SEP 17

$RAREHighAI 9/10

US FDA approves Ultragenyx's gene therapy for rare disorder

The US FDA has approved a gene therapy developed by Ultragenyx Pharmaceutical Inc. for the treatment of a rare disorder. The therapy, designed for patients with a specific genetic condition, marks a significant milestone in the company's pipeline. According to the FDA, this approval provides a new treatment option for a previously underserved patient population.

tradingview.com1 min

Ultragenyx Stock Crashes As GTX-102 Failure Erases Optimism

The 30-second read

Why it matters

Market read

What to watch

Background

Ticker impact

Market effects

Counterpoint

Key entities

Also covered by

Related articles

RARE Looks 68.1% Undervalued on GF Value™ After FDA Approval Boo

Ultragenyx Pharmaceutical Inc. (RARE): Other Events

A fatal childhood disease gets its first FDA-approved treatment

Ultragenyx stock surges 10% on FDA approval for gene therapy

Ultragenyx gets FDA approval for rare disease gene therapy

US FDA approves Ultragenyx's gene therapy for rare disorder